Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39


Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro.

Queenan AM, Dowling DJ, Cheng WK, Faé K, Fernandez J, Flynn PJ, Joshi S, Brightman SE, Ramirez J, Serroyen J, Wiertsema S, Fortanier A, van den Dobbelsteen G, Levy O, Poolman J.

Vaccine. 2019 Jan 3;37(1):80-89. doi: 10.1016/j.vaccine.2018.11.028. Epub 2018 Nov 23.


Clinical Manifestations and Molecular Characterization of Pertactin-Deficient and Pertactin-Producing Bordetella pertussis in Children, Philadelphia 2007-2014.

Vodzak J, Queenan AM, Souder E, Evangelista AT, Long SS.

Clin Infect Dis. 2017 Jan 1;64(1):60-66. Epub 2016 Sep 13.


The mouse intranasal challenge model for potency testing of whole-cell pertussis vaccines.

Queenan AM, Fernandez J, Shang W, Wiertsema S, van den Dobbelsteen GP, Poolman J.

Expert Rev Vaccines. 2014 Oct;13(10):1265-70. doi: 10.1586/14760584.2014.938642. Epub 2014 Jul 17.


In memoriam: John P. Quinn, MD.

Perez F, Arias CA, Bush K, Drusano GL, Lolans K, Munoz-Price LS, Nicolau DP, Queenan AM, Rice LB, Segreti J, Shlaes DM, Weinstein RA, Bonomo RA.

Clin Infect Dis. 2014 Mar;58(5):748-50. doi: 10.1093/cid/cit801. Epub 2013 Dec 12. No abstract available.


Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States.

Pawloski LC, Queenan AM, Cassiday PK, Lynch AS, Harrison MJ, Shang W, Williams MM, Bowden KE, Burgos-Rivera B, Qin X, Messonnier N, Tondella ML.

Clin Vaccine Immunol. 2014 Feb;21(2):119-25. doi: 10.1128/CVI.00717-13. Epub 2013 Nov 20.


Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients.

Queenan AM, Davies TA, He W, Lynch AS.

J Chemother. 2013 Jun;25(3):141-7. doi: 10.1179/1973947813Y.0000000074.


Pertactin-negative variants of Bordetella pertussis in the United States.

Queenan AM, Cassiday PK, Evangelista A.

N Engl J Med. 2013 Feb 7;368(6):583-4. doi: 10.1056/NEJMc1209369. No abstract available.


Detection systems for carbapenemase gene identification should include the SME serine carbapenemase.

Bush K, Pannell M, Lock JL, Queenan AM, Jorgensen JH, Lee RM, Lewis JS, Jarrett D.

Int J Antimicrob Agents. 2013 Jan;41(1):1-4. doi: 10.1016/j.ijantimicag.2012.08.008. Epub 2012 Dec 4.


Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010.

Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, Peterson J, Davies TA.

Diagn Microbiol Infect Dis. 2012 Jul;73(3):267-70. doi: 10.1016/j.diagmicrobio.2012.04.002. Epub 2012 May 12.


Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.

Fernandez J, Abbanat D, Shang W, He W, Amsler K, Hastings J, Queenan AM, Melton JL, Barron AM, Flamm RK, Lynch AS.

Antimicrob Agents Chemother. 2012 Mar;56(3):1476-84. doi: 10.1128/AAC.06057-11. Epub 2012 Jan 9.


Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2.

Morrow BJ, Abbanat D, Baum EZ, Crespo-Carbone SM, Davies TA, He W, Shang W, Queenan AM, Lynch AS.

Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21. doi: 10.1128/AAC.00470-11. Epub 2011 Sep 12.


Detection of 2 SME-1 carbapenemase-producing Serratia marcescens in Detroit.

Fairfax MR, Queenan AM, Lephart PR, Kaye KS, Dror M, Arnous N, Salimnia TT, Mitchell RA, Alangaden G, Salimnia H.

Diagn Microbiol Infect Dis. 2011 Nov;71(3):325-6. doi: 10.1016/j.diagmicrobio.2011.06.007. Epub 2011 Aug 15. No abstract available.


Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009.

Snydman DR, Jacobus NV, McDermott LA, Golan Y, Goldstein EJ, Harrell L, Jenkins S, Newton D, Pierson C, Rosenblatt J, Venezia R, Gorbach SL, Queenan AM, Hecht DW.

Anaerobe. 2011 Aug;17(4):147-51. doi: 10.1016/j.anaerobe.2011.05.014. Epub 2011 Jun 2.


Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.

Queenan AM, Shang W, Bush K, Flamm RK.

Antimicrob Agents Chemother. 2010 Oct;54(10):4092-7. doi: 10.1128/AAC.00060-10. Epub 2010 Jul 6.


Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.

Louie A, Bied A, Fregeau C, Van Scoy B, Brown D, Liu W, Bush K, Queenan AM, Morrow B, Khashab M, Kahn JB, Nicholson S, Kulawy R, Drusano GL.

Antimicrob Agents Chemother. 2010 Jun;54(6):2638-45. doi: 10.1128/AAC.01721-09. Epub 2010 Mar 22.


Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.

Queenan AM, Shang W, Flamm R, Bush K.

Antimicrob Agents Chemother. 2010 Jan;54(1):565-9. doi: 10.1128/AAC.01004-09. Epub 2009 Nov 2.


New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.

Schneider I, Queenan AM, Markovska R, Markova B, Keuleyan E, Bauernfeind A.

Antimicrob Agents Chemother. 2009 Oct;53(10):4518-21. doi: 10.1128/AAC.00461-09. Epub 2009 Jul 20.


Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.

Baum EZ, Crespo-Carbone SM, Morrow BJ, Davies TA, Foleno BD, He W, Queenan AM, Bush K.

Antimicrob Agents Chemother. 2009 Jul;53(7):2785-90. doi: 10.1128/AAC.00018-09. Epub 2009 May 11.


VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.

Schneider I, Keuleyan E, Rasshofer R, Markovska R, Queenan AM, Bauernfeind A.

Antimicrob Agents Chemother. 2008 Aug;52(8):2977-9. doi: 10.1128/AAC.00175-08. Epub 2008 Jun 2.


Carbapenemases: the versatile beta-lactamases.

Queenan AM, Bush K.

Clin Microbiol Rev. 2007 Jul;20(3):440-58, table of contents. Review.


Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.

Queenan AM, Shang W, Kania M, Page MG, Bush K.

Antimicrob Agents Chemother. 2007 Sep;51(9):3089-95. Epub 2007 Jun 25.


SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing beta-lactamases.

Queenan AM, Shang W, Schreckenberger P, Lolans K, Bush K, Quinn J.

Antimicrob Agents Chemother. 2006 Oct;50(10):3485-7.


Amp C beta-lactamase-producing Escherichia coli in neonatal meningitis: diagnostic and therapeutic challenge.

Fakioglu E, Queenan AM, Bush K, Jenkins SG, Herold BC.

J Perinatol. 2006 Aug;26(8):515-7.


Novel carbapenem-hydrolyzing oxacillinase OXA-62 from Pandoraea pnomenusa.

Schneider I, Queenan AM, Bauernfeind A.

Antimicrob Agents Chemother. 2006 Apr;50(4):1330-5.


First detection of metallo-beta-lactamase VIM-2 in Pseudomonas aeruginosa isolates from Colombia.

Villegas MV, Lolans K, del Rosario Olivera M, Suarez CJ, Correa A, Queenan AM, Quinn JP; Colombian Nosocomial Resistance Study Group.

Antimicrob Agents Chemother. 2006 Jan;50(1):226-9.


CTX-M-15 extended-spectrum (beta)-lactamase from Nigerian Klebsiella pneumoniae.

Soge OO, Queenan AM, Ojo KK, Adeniyi BA, Roberts MC.

J Antimicrob Chemother. 2006 Jan;57(1):24-30. Epub 2005 Nov 30.


First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States.

Lolans K, Queenan AM, Bush K, Sahud A, Quinn JP.

Antimicrob Agents Chemother. 2005 Aug;49(8):3538-40.


Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2.

Yigit H, Queenan AM, Rasheed JK, Biddle JW, Domenech-Sanchez A, Alberti S, Bush K, Tenover FC.

Antimicrob Agents Chemother. 2003 Dec;47(12):3881-9.


Biochemical characterization of beta-lactamases Bla1 and Bla2 from Bacillus anthracis.

Materon IC, Queenan AM, Koehler TM, Bush K, Palzkill T.

Antimicrob Agents Chemother. 2003 Jun;47(6):2040-2.


TEM-71, a novel plasmid-encoded, extended-spectrum beta-lactamase produced by a clinical isolate of Klebsiella pneumoniae.

Rasheed JK, Anderson GJ, Queenan AM, Biddle JW, Oliver A, Jacoby GA, Bush K, Tenover FC.

Antimicrob Agents Chemother. 2002 Jun;46(6):2000-3.


Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime.

Wong-Beringer A, Hindler J, Loeloff M, Queenan AM, Lee N, Pegues DA, Quinn JP, Bush K.

Clin Infect Dis. 2002 Jan 15;34(2):135-46. Epub 2001 Dec 4.


Detection of multiresistant ceftazidime-susceptible Klebsiella pneumoniae isolates lacking TEM-26 after class restriction of cephalosporins.

Urban C, Mariano N, Rahman N, Queenan AM, Montenegro D, Bush K, Rahal JJ.

Microb Drug Resist. 2000 Winter;6(4):297-303.


Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae.

Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC.

Antimicrob Agents Chemother. 2001 Apr;45(4):1151-61. Erratum in: Antimicrob Agents Chemother. 2008 Feb;52(2):809.


SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains.

Queenan AM, Torres-Viera C, Gold HS, Carmeli Y, Eliopoulos GM, Moellering RC Jr, Quinn JP, Hindler J, Medeiros AA, Bush K.

Antimicrob Agents Chemother. 2000 Nov;44(11):3035-9.


Characterization of the extended-spectrum beta-lactamase reference strain, Klebsiella pneumoniae K6 (ATCC 700603), which produces the novel enzyme SHV-18.

Rasheed JK, Anderson GJ, Yigit H, Queenan AM, Doménech-Sánchez A, Swenson JM, Biddle JW, Ferraro MJ, Jacoby GA, Tenover FC.

Antimicrob Agents Chemother. 2000 Sep;44(9):2382-8.


Supplemental Content

Loading ...
Support Center